RxDoctor Payments Data

Amanda Paradeaux

Family · Odessa, TXNPI 1609128594

Payments from drug & device makers

$2,838in general payments, 2019–2025

Across 160 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$891
  • Novo Nordisk$282
  • Pfizer$281
  • GSK$270
  • AstraZeneca$264
  • AbbVie$222
  • plus $628 from 10 others

What the payments were for

  • Food & beverage$2,838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,838 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$35,429
Medicare patients
136
Services billed
881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$36,805
JardianceEmpagliflozin22$28,713
OzempicSemaglutide13$24,915
TrulicityDulaglutide15$20,823
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$16,389
MounjaroTirzepatide11$14,465
EliquisApixaban11$11,118
Tresiba Flextouch U-200Insulin Degludec15$10,748
LinzessLinaclotide11$9,866
Insulin Lispro Kwikpen U-100Insulin Lispro15$5,908
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,474
Albuterol Sulfate HfaAlbuterol Sulfate97$2,430
Atorvastatin Calcium234$2,055
Levothyroxine Sodium176$2,048
Gabapentin90$1,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$270$36,80537 claims
Lilly USA, LLCTrulicity, Mounjaro$891$35,28826 claims
Boehringer IngelheimJardiance$168$28,71322 claims
Novo NordiskOzempic$282$24,91513 claims
AstraZenecaBreztri Aerosphere$264$16,38917 claims
PfizerEliquis$281$11,11811 claims
AbbVieLinzess, Synthroid$222$10,90631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →